Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians.
about
Therapeutic modalities in diabetic nephropathy: standard and emerging approaches.Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studiesCreating a conversation: insights from the development of a decision aidA critical dialogue: communicating with type 2 diabetes patients about cardiovascular riskAspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treIndividualising therapy for older adults with diabetes mellitusManagement of Diabetic Nephropathy in the Elderly: Special Considerations.Combination therapy of dyslipidemia in non-insulin-dependent diabetes mellitus and the metabolic syndrome.Sources of evidence for systematic reviews of interventions in diabetes.Cardiovascular risk and statin use in the United StatesShifting the disease management paradigm from glucose: what are the pros?Cardiovascular disease in type 2 diabetes: Attributable risk due to modifiable risk factors.Should Statins Be Started In All Type 2 Diabetics Irrespective of LDL-Cholesterol Level?All-cause mortality risk among a national sample of individuals with diabetes.Does use of pooled cohort risk score overestimate the use of statin?: a retrospective cohort study in a primary care settingEfficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trialsEffectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy: randomised controlled trialThe impact of a diabetes local enhanced service on quality outcome framework diabetes outcomes.Simultaneous control of intermediate diabetes outcomes among Veterans Affairs primary care patients.Prioritization of care in adults with diabetes and comorbidity.Treatment of lipids and type 2 diabetes.Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus.Cardiovascular prevention in type 2 diabetic patients: review of efficacious treatments.Effects of rosuvastatin and/or β-carotene on non-alcoholic fatty liver in ratsHyperglycemia, lipoprotein glycation, and vascular disease.Drug insight: statins and gastrointestinal cancer.Type II diabetes mellitus and cardiovascular risk factors: Current therapeutic approachesThe complexity of medication regimens and test ordering for patients with diabetes from 1995 to 2003Nigerian Honey Ameliorates Hyperglycemia and Dyslipidemia in Alloxan-Induced Diabetic Rats.Quality of diabetes care and coronary heart disease absolute risk in patients with type 2 diabetes mellitus in Australian general practice.Negative trials in nephrology: what can we learn?High cardiovascular risk in patients with diabetes and the cardiometabolic syndrome: mandate for statin therapy.Antidepressant use and new-onset diabetes: a systematic review and meta-analysis.Assessing appropriateness of lipid management among patients with diabetes mellitus: moving from target to treatment.Pleiotropic effects of rosuvastatin on the glucose metabolism and the subcutaneous and visceral adipose tissue behavior in C57Bl/6 miceThe association of patient age with cardiovascular disease risk factor treatment and control in diabetes.Comparison of demographic factors and cardiovascular risk factor control among U.S. adults with type 2 diabetes by insulin treatment classification.Effects of a Combination of Berberis aristata, Silybum marianum and Monacolin on Lipid Profile in Subjects at Low Cardiovascular Risk; A Double-Blind, Randomized, Placebo-Controlled Trial.Considerations and treatment options for patients with comorbid atrial fibrillation and diabetes mellitus.Country of birth, socioeconomic factors, and risk factor control in patients with type 2 diabetes: a Swedish study from 25 primary health-care centres.
P2860
Q27007027-EA30ABD6-6F8D-4315-B315-E59AD06F0221Q28072161-1C88571F-BB88-43CE-BAED-6834E840661DQ28219217-353C0C6A-87E5-4FFF-B6A0-F4D767A078EDQ28219258-24363DA4-D961-4733-8715-09FF1BEA8BA9Q28220363-14494A95-DC45-424B-A204-C7D83A02845BQ28222223-E7C390F2-D432-44AE-9ECE-6AA6F91785E3Q30353386-098CBF1A-E3A2-4B4B-B293-18E0942C5BC9Q30434678-5DAFA500-5794-44E1-AA50-879DF360D1B9Q33223698-08B81CD2-CCC2-49F6-B762-4CEB7DB37E63Q33599663-ED2BA0E2-159E-4350-BFD2-3BC745E1A0F6Q33610665-C4703167-CAF5-4952-BD6A-327EFFCC05B4Q34062652-08B29B6A-5FF8-40E2-9F48-CBCBFAB9DA6AQ34220526-6DF8BC9A-CE6F-45A0-83FA-D47572077358Q34237363-8A94707C-804A-4D51-9FB6-25F0459D394EQ34537368-E44BA8EF-9E38-4378-85A7-287A12085D36Q34601330-6C8D929F-93E7-472D-8A6D-94A625E8C760Q35021652-1A26DFF0-70BB-4882-8B02-8A47DF87950CQ35073167-8B8ECAC1-2CCC-41D1-B142-FD0AB75A9E9DQ35696136-939CC96C-4716-4D84-83F9-C75B299053BCQ35798114-6BC6CE1D-8D84-4CB4-8288-23878AB3192AQ35918843-094D9514-17A9-45E1-B90B-CBDA65081F73Q35989422-D6DB7E29-C06A-4A84-93C3-912CCF789ED7Q36093161-34D58BBA-BBC6-47B2-9B23-ED9A61EC490EQ36216714-7474DA0F-F3DE-4CC2-8513-343796FC821FQ36218217-CFD03A25-3A80-4AC9-9ACA-7E29B3929A7AQ36606882-054B377E-C317-446F-B0B8-9663C9519932Q36608474-6D5E105B-27C0-4BCC-9874-AB35C2257F61Q36625815-7DC603AA-17A4-4A09-98A3-1241556A0A9CQ36731956-F896791D-3868-4BA1-B4DD-346ACACB6146Q36767136-548EC137-61B4-4A6A-A831-4F67F9C8CF25Q36863406-1E8B747A-0F29-4634-9C2B-271FEB815D44Q36902749-B37C6677-0D19-4DAF-8F96-C5C34E55230DQ36956027-EE7D50E8-B4A8-42B3-A367-62A08E2A9248Q36975446-D436B845-A95D-47D7-A1F5-6F21EE3EAFEFQ37028323-3F00BACC-AFFD-4D7D-8A1E-340E3D7333E9Q37305215-BDE0CDD2-7AD7-418A-BE23-6D047CFA39D6Q37596843-2544EAA0-EA0D-4B16-9E64-E699EA452F8FQ37690832-35E49492-19E3-4B16-844E-6A0414271627Q39409421-5DD99455-0AA1-4B87-993E-FE7C7B0396C1Q39784448-D3A69D69-9DDD-4C5E-B7DE-7B0D7785649D
P2860
Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians.
description
2004 nî lūn-bûn
@nan
2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Pharmacologic lipid-lowering t ...... merican College of Physicians.
@ast
Pharmacologic lipid-lowering t ...... merican College of Physicians.
@en
type
label
Pharmacologic lipid-lowering t ...... merican College of Physicians.
@ast
Pharmacologic lipid-lowering t ...... merican College of Physicians.
@en
prefLabel
Pharmacologic lipid-lowering t ...... merican College of Physicians.
@ast
Pharmacologic lipid-lowering t ...... merican College of Physicians.
@en
P2093
P1476
Pharmacologic lipid-lowering t ...... merican College of Physicians.
@en
P2093
American College of Physicians
Rodney A Hayward
Sandeep Vijan
P304
P356
10.7326/0003-4819-140-8-200404200-00013
P407
P577
2004-04-01T00:00:00Z